TICKERNERD
Menu
INDVINDVHealthcare · Drug Manufacturers - Specialty & Generic

INDV Stock Forecast: Indivior Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$36
−1.84% on the day

The 4 Wall Street analysts covering Indivior Pharmaceuticals, Inc. hold a median 12-month price target of $50 — +38.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.4B
Ticker Nerd rank
97 / 100
Median analyst target
$50
Analysts covering
4
Revenue$343.0M+13.6% y/y
Operating income$159.0M
Net income$122.0M
Free cash flow$222.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.4%
1M
−10.7%
YTD
+0.9%
1Y
+48.8%
From 52W high
−13.5%
From 52W low
+60.8%
$23
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INDV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Indivior Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Revisions
97
Value
95
Volatility
91
Momentum
90
Growth
83
Issuance
54
Size
26
Accruals
25

Quality (98): The business earns solid, repeatable profits on what it owns.

Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INDV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INDV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40$45$50$55Oct 25Jan 26Apr 26Jul 26INDVHigh $53Median $50Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $43Median $50High $53

The green dot is the last close — the median target sits +38.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026BarclaysMaintainsOverweight$46 → $43
18 June 2026BarclaysInitiatesOverweight$46
18 June 2026BarclaysInitiatesOverweight—
12 Jan 2026HC Wainwright & Co.MaintainsBuy—
31 Oct 2025Piper SandlerReiteratesOverweight—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
27 Aug 2025Craig-HallumMaintainsBuy—
6 Aug 2025HC Wainwright & Co.InitiatesBuy—
22 July 2025JefferiesAssumesBuy$20
30 June 2025Craig-HallumMaintainsBuy—
6 Mar 2025Piper SandlerMaintainsOverweight—
25 Oct 2024Piper SandlerReiteratesOverweight—
11 Oct 2024Craig-HallumMaintainsBuy—
11 Oct 2024Piper SandlerReiteratesOverweight—
13 Sept 2024Piper SandlerReiteratesOverweight—
23 July 2024Piper SandlerInitiatesOverweight—
10 July 2024Craig-HallumMaintainsBuy—
3 Apr 2024Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INDV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INDV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Indivior Pharmaceuticals, Inc. returned +48.8% against +19.6% for the S&P 500, dividends included.

INDV vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Oct 25Jan 26Apr 26Jul 26INDVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INDV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+14.4%
Analysts raising
2
Analysts cutting
0
Fundamentals

Indivior Pharmaceuticals, Inc. (INDV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.2×

Cheaper than 51% of US stocks

Price / sales
3.3×

Cheaper than 39% of US stocks

Price / book
−21.0×

Cheaper than 98% of US stocks

EV / EBITDA
8.1×

Cheaper than 46% of US stocks

Growth & margins
Revenue growth (YoY)
13.6%

Higher than 60% of US stocks

Earnings growth (YoY)
577.8%

Higher than 96% of US stocks

Gross margin
85.4%

Higher than 94% of US stocks

Operating margin
46.9%

Higher than 95% of US stocks

Net margin
26.7%

Higher than 87% of US stocks

Returns & dividend
Return on equity
−212.1%

Higher than 7% of US stocks

Return on assets
26.4%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Indivior Pharmaceuticals, Inc. (INDV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Indivior Pharmaceuticals, Inc. has a market value of $4.4B and an enterprise value of $4.6B.

  • Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 13.6% year on year.

  • Net income over the same four quarters: $355.0M, a 26.7% net margin.

  • Diluted earnings per share, trailing twelve months: $2.79.

  • Free cash flow in the twelve months to 30 June 2026: −$111.0M.

  • Indivior Pharmaceuticals, Inc. spent $302.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 118.0M.

  • Trailing P/E: 13.2×; forward P/E: 7.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Indivior Pharmaceuticals, Inc. employs 827 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

INDV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
INDVIndivior Pharmaceuticals, Inc.$4.4B
97
AMLXAmylyx Pharmaceuticals, Inc.$4.1B
56
AMRXAmneal Pharmaceuticals, Inc.$5.6B
80
LQDALiquidia Corp.$5.9B
78
KNSAKiniksa Pharmaceuticals International Plc$6.1B
98
LNTHLantheus Holdings, Inc.$6.5B
86
SUPNSupernus Pharmaceuticals, Inc.$2.6B
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Indivior Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INDV news & analysis

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

Zacks Investment Research · 21 Aug 2026neutral

Indivior has proposed a merger with Supernus that, according to Zacks Investment Research, could broaden its central nervous system portfolio, cut costs, and reduce its reliance on the Sublocade product. However, the closing of the deal remains uncertain.

Why it matters — An INDV watcher would care because the merger could meaningfully diversify Indivior's growth engine and lower dependence on a single product, though completion is not yet assured.

Here's Why Indivior Pharmaceuticals Inc. (INDV) is a Strong Growth Stock

Zacks Investment Research · 13 Aug 2026positive

Zacks Investment Research highlighted Indivior Pharmaceuticals Inc. (INDV) as a strong growth stock using its Style Scores system, which helps investors identify top-rated stocks based on investing style.

Why it matters — The article positions INDV as a favorably rated stock according to Zacks' quantitative screening model, which could influence investor perception.

Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks Investment Research · 11 Aug 2026positive

Zacks Investment Research published an analysis stating that Indivior Pharmaceuticals Inc. (INDV) has solid growth attributes that could help it outperform the market.

Why it matters — The article suggests INDV has favorable growth characteristics, which could influence investor perception of the company's potential.

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Business Wire · 7 Aug 2026neutral

Law firm Kahn Swick & Foti, LLC has announced an investigation into the proposed acquisition of Supernus Pharmaceuticals by Indivior Pharmaceuticals, examining the adequacy of the price and process of the deal, under which Supernus shareholders would receive 1.5401 Indivior common shares per Supernus share.

Why it matters — Indivior watchers may want to note that its planned acquisition of Supernus is now subject to shareholder-focused legal scrutiny over the deal's price and process.

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Zacks Investment Research · 4 Aug 2026positive

Indivior announced a merger with Supernus to form a CNS-focused biopharma company. The company also topped second-quarter earnings and revenue estimates and raised its 2026 outlook.

Why it matters — INDV watchers would care because the merger signals a strategic shift in the company's structure, while the earnings beat and higher 2026 outlook point to stronger-than-expected current performance.

FAQ

Frequently asked questions about INDV stock

What is the INDV stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Indivior Pharmaceuticals, Inc. have a median 12-month price target of $50, with estimates ranging from $43 to $53. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INDV stock a buy right now?

Of the 4 analysts covering Indivior Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Indivior Pharmaceuticals, Inc. 97 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INDV?

As at 22 Aug 2026, Indivior Pharmaceuticals, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will INDV stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +38.2% from the last close, and Ticker Nerd's factor model ranks Indivior Pharmaceuticals, Inc. 97 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INDV stock forecast for 2030?

No analyst covering Indivior Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INDV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $53 over the next 12 months.

How has INDV stock performed over the past year?

Indivior Pharmaceuticals, Inc. returned +48.8% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Indivior Pharmaceuticals, Inc. do?

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on treating substance use disorders and related mental health conditions.

What is the latest news on INDV?

The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026". Indivior has proposed a merger with Supernus that, according to Zacks Investment Research, could broaden its central nervous system portfolio, cut costs, and reduce its reliance on the Sublocade product. However, the closing of the deal remains uncertain.

Company

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on treating substance use disorders and related mental health conditions. The company concentrates on evidence-based therapies for opioid use disorder, including long-acting injectable and sublingual formulations designed to support adherence and sustained recovery. Its portfolio also extends to treatments addressing opioid overdose, alcohol dependence, and other addiction-related indications, positioning it as a key player in addiction medicine. Indivior Pharmaceuticals, Inc. integrates neuroscience, clinical research, and real-world data to develop and optimize therapies for chronic, relapsing conditions associated with substance use. The company works with healthcare providers, treatment centers, and public health systems, supplying products and clinical support across multiple regions. Founded in 1994 and headquartered in the United States, Indivior Pharmaceuticals, Inc. plays a significant role in the global effort to address opioid use disorder and other substance-related health burdens through specialized pharmacological treatments.

CEO Mr. Joseph J. Ciaffoni · 827 employees · United States · https://www.indivior.com